The announcement that a draft Brexit deal has been negotiated between the UK and the EU and agreed by the UK Cabinet was greeted with some relief by the life sciences industry as offering a degree of certainty for the sector, not least because of the proposed transition period in the agreement that would avoid a “cliff-edge” Brexit in March next year.
It is far from clear whether the draft agreement will in fact become the final deal, but Mike Thompson, CEO of the Association of the British Pharmaceutical Industry (ABPI), said a transition period would mean that “our members can
